Non-Cystic Fibrosis Bronchiectasis Market Set to Grow Substantially Through 2034, DelveInsight Projects | Insmed, AstraZeneca, Zambion, The Marcus Foundation, Chiesi Farmaceutici, SolAeroMed

DelveInsight's "Non-Cystic Fibrosis Bronchiectasis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Non-Cystic Fibrosis Bronchiectasis, historical and forecasted epidemiology as well as the Non-Cystic Fibrosis Bronchiectasis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Non-Cystic Fibrosis Bronchiectasis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Non-Cystic Fibrosis Bronchiectasis Market Forecast
https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Non-Cystic Fibrosis Bronchiectasis Market Report:
• The Non-Cystic Fibrosis Bronchiectasis market size was valued approximately USD 1,725 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In April 2025, Brensocatib demonstrated a significant reduction in the annualized rate of pulmonary exacerbations and decline in lung function compared to placebo in patients with non-cystic fibrosis bronchiectasis, as reported in the Phase III ASPEN trial (NCT04594369) results published in The New England Journal of Medicine (NEJM). This chronic and progressive condition is associated with frequent exacerbations, deteriorating lung function, and diminished quality of life, increasing the risk of early mortality from various causes. In recognition of the positive data from the ASPEN trial, the FDA granted Priority Review status to the New Drug Application (NDA) for brensocatib in this patient group in February.
• In February 2025, The FDA has granted Priority Review status to brensocatib, an investigational therapy for patients with non-cystic fibrosis bronchiectasis. With the acceptance of the New Drug Application (NDA), a target action date has been set for August 12, 2025. If approved, brensocatib would become the first and only authorized treatment specifically for bronchiectasis. Additionally, it would represent the first approval in a new therapeutic class-dipeptidyl peptidase 1 (DPP1) inhibitors-designed to address neutrophil-mediated diseases. This regulatory milestone underscores the potential significance of brensocatib in addressing a major unmet medical need in respiratory care.
• In February 2025, Verona Pharma was a biopharmaceutical company focused on developing and commercializing innovative therapies for chronic respiratory diseases with significant unmet needs. Its first commercial product, OhtuvayreTM (ensifentrine), is a novel inhaled treatment for COPD maintenance that uniquely delivers both bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Ensifentrine also holds promise for addressing other respiratory conditions, including non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and more.
• In December 2024, Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a biotechnology company specializing in high-purity, targeted bacteriophage therapies for chronic lung diseases and antibiotic-resistant infections, has announced promising topline results from its Phase 2 "Tailwind" clinical trial. This study is evaluating AP-PA02, an innovative inhaled multi-phage therapy designed to treat chronic Pseudomonas aeruginosa infections in individuals with non-cystic fibrosis bronchiectasis (NCFB).
• In July 2024, Armata Pharmaceuticals has announced the completion of patient enrollment for its Phase II Tailwind clinical trial, which is assessing the efficacy of inhaled AP-PA02 in individuals with non-cystic fibrosis bronchiectasis (NCFB) and chronic Pseudomonas aeruginosa infection.
• The total market size for the EU4 and the UK was estimated at around USD 524 million in 2023.
• In 2023, the market size for NCFB in the US was estimated at around USD 762 million and is expected to grow throughout the forecast period.
• DelveInsight's estimates show that, among the EU4 and the UK, the UK had the largest market size in 2023 at approximately USD 196 million, followed by Spain with around USD 151 million, and Italy at USD 90 million for the same year.
• In 2023, Japan's total market size for NCFB was approximately USD 439 million, accounting for nearly 25% of the total market revenue across the 7MM.
• DelveInsight's epidemiology model estimated around 1.4 million diagnosed prevalent cases of Non-Cystic Fibrosis Bronchiectasis in the 7MM in 2023. This number is expected to rise over the forecast period (2024-2034) due to growing awareness and advancements in diagnostic procedures.
• In 2023, the United States had approximately 371,000 diagnosed prevalent cases of Non-Cystic Fibrosis Bronchiectasis, accounting for about 27% of the total cases in the 7MM.
• In the US, the number of females diagnosed with NCFB is higher than that of males. In 2023, females represented around 244,000 cases, compared to approximately 127,000 cases in males. These figures are projected to increase throughout the study period (2020-2034).
• In the EU4 and the UK, the prevalence of moderate Non-Cystic Fibrosis Bronchiectasis (NCFB) cases is the highest, followed by mild and severe cases. In 2023, there were around 198,000 moderate, 153,000 mild, and 143,000 severe NCFB cases, with these numbers expected to rise throughout the forecast period.
• In 2023, Japan had approximately 98,000 NCFB cases linked to post-infection, 5,000 to COPD, 7,000 to immunodeficiency, 6,000 to asthma, 206,000 to other causes, and 166,000 cases with unknown or idiopathic etiologies.
• In 2023, estimates suggest that Japan reported around 132,000 cases of Pseudomonas aeruginosa, 112,000 cases of Haemophilus influenzae, 39,000 cases of Streptococcus pneumoniae, 97,000 cases classified as other pathogens, and 107,000 cases with no growth in the microbiology of NCFB patients.
• Key Non-Cystic Fibrosis Bronchiectasis Companies: Boehringer Ingelheim, Zambon, Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc., Chiesi Farmaceutici S.p.A., SolAeroMed Inc., Zambon SpA, Boehringer Ingelheim, Renovion, Inc., Novartis, Alaxia SAS, and others
• Key Non-Cystic Fibrosis Bronchiectasis Therapies: CMS I-neb, BI 1291583, Brensocatib, Colistimethatesodium, Trikafta, CHF 6333, S-1226, CMS, BI 1323495, ARINA-1, TIP, ALX-009, and others
• The Non-Cystic Fibrosis Bronchiectasis epidemiology based on gender analyzed that in the US, females diagnosed with NCFB are higher in number than males.
• The Non-Cystic Fibrosis Bronchiectasis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Cystic Fibrosis Bronchiectasis pipeline products will significantly revolutionize the Non-Cystic Fibrosis Bronchiectasis market dynamics.

Non-Cystic Fibrosis Bronchiectasis Overview
Non-cystic fibrosis bronchiectasis (NCFB) is a chronic respiratory condition characterized by the abnormal widening and inflammation of the bronchial tubes in the lungs. Unlike cystic fibrosis (CF)-related bronchiectasis, which is caused by genetic mutations affecting the production of mucus, NCFB occurs in individuals without CF.

Get a Free sample for the Non-Cystic Fibrosis Bronchiectasis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Non-Cystic Fibrosis Bronchiectasis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Non-Cystic Fibrosis Bronchiectasis Epidemiology Segmentation:
The Non-Cystic Fibrosis Bronchiectasis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Non-Cystic Fibrosis Bronchiectasis
• Prevalent Cases of Non-Cystic Fibrosis Bronchiectasis by severity
• Gender-specific Prevalence of Non-Cystic Fibrosis Bronchiectasis
• Diagnosed Cases of Episodic and Chronic Non-Cystic Fibrosis Bronchiectasis

Download the report to understand which factors are driving Non-Cystic Fibrosis Bronchiectasis epidemiology trends @ Non-Cystic Fibrosis Bronchiectasis Epidemiology Forecast
https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Non-Cystic Fibrosis Bronchiectasis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Cystic Fibrosis Bronchiectasis market or expected to get launched during the study period. The analysis covers Non-Cystic Fibrosis Bronchiectasis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Non-Cystic Fibrosis Bronchiectasis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Non-Cystic Fibrosis Bronchiectasis Therapies and Key Companies
• CMS I-neb: Zambon
• BI 1291583: Boehringer Ingelheim
• Brensocatib: Insmed/ AstraZeneca
• Colistimethatesodium: Zambion
• Trikafta: The Marcus Foundation, Inc.
• CHF 6333: Chiesi Farmaceutici S.p.A.
• S-1226: SolAeroMed Inc.
• CMS: Zambon SpA
• BI 1323495: Boehringer Ingelheim
• ARINA-1: Renovion, Inc.
• TIP: Novartis
• ALX-009: Alaxia SAS

Discover more about therapies set to grab major Non-Cystic Fibrosis Bronchiectasis market share @ Non-Cystic Fibrosis Bronchiectasis Treatment Landscape
https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Non-Cystic Fibrosis Bronchiectasis Market Strengths
• Increasing disease prevalence due to better detection rate with advanced imaging techniques and improved awareness.
• An improved understanding of disease pathophysiology has improved diagnosis and is useful in determining novel target molecules for treatment development.

Non-Cystic Fibrosis Bronchiectasis Market Opportunities
• Large, positive, randomized controlled trials are necessary to set the standard of care for bronchiectasis patients.
• Vaccines and monoclonal antibodies, though partially useful, there is a need for evidence-based studies to use for the prevention of PA chronic colonization in bronchiectasis patients.

Scope of the Non-Cystic Fibrosis Bronchiectasis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Non-Cystic Fibrosis Bronchiectasis Companies: Boehringer Ingelheim, Zambon, Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc., Chiesi Farmaceutici S.p.A., SolAeroMed Inc., Zambon SpA, Boehringer Ingelheim, Renovion, Inc., Novartis, Alaxia SAS, and others
• Key Non-Cystic Fibrosis Bronchiectasis Therapies: CMS I-neb, BI 1291583, Brensocatib, Colistimethatesodium, Trikafta, CHF 6333, S-1226, CMS, BI 1323495, ARINA-1, TIP, ALX-009, and others
• Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment: Non-Cystic Fibrosis Bronchiectasis current marketed and Non-Cystic Fibrosis Bronchiectasis emerging therapies
• Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Non-Cystic Fibrosis Bronchiectasis market drivers and Non-Cystic Fibrosis Bronchiectasis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Non-Cystic Fibrosis Bronchiectasis Unmet Needs, KOL's views, Analyst's views, Non-Cystic Fibrosis Bronchiectasis Market Access and Reimbursement

To know more about Non-Cystic Fibrosis Bronchiectasis companies working in the treatment market, visit @ Non-Cystic Fibrosis Bronchiectasis Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Non-Cystic Fibrosis Bronchiectasis Market Report Introduction
2. Executive Summary for Non-Cystic Fibrosis Bronchiectasis
3. SWOT analysis of Non-Cystic Fibrosis Bronchiectasis
4. Non-Cystic Fibrosis Bronchiectasis Patient Share (%) Overview at a Glance
5. Non-Cystic Fibrosis Bronchiectasis Market Overview at a Glance
6. Non-Cystic Fibrosis Bronchiectasis Disease Background and Overview
7. Non-Cystic Fibrosis Bronchiectasis Epidemiology and Patient Population
8. Country-Specific Patient Population of Non-Cystic Fibrosis Bronchiectasis
9. Non-Cystic Fibrosis Bronchiectasis Current Treatment and Medical Practices
10. Non-Cystic Fibrosis Bronchiectasis Unmet Needs
11. Non-Cystic Fibrosis Bronchiectasis Emerging Therapies
12. Non-Cystic Fibrosis Bronchiectasis Market Outlook
13. Country-Wise Non-Cystic Fibrosis Bronchiectasis Market Analysis (2020-2034)
14. Non-Cystic Fibrosis Bronchiectasis Market Access and Reimbursement of Therapies
15. Non-Cystic Fibrosis Bronchiectasis Market Drivers
16. Non-Cystic Fibrosis Bronchiectasis Market Barriers
17. Non-Cystic Fibrosis Bronchiectasis Appendix
18. Non-Cystic Fibrosis Bronchiectasis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Non-Cystic Fibrosis Bronchiectasis Pipeline https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Non-Cystic Fibrosis Bronchiectasis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Non-Cystic Fibrosis Bronchiectasis market. A detailed picture of the Non-Cystic Fibrosis Bronchiectasis pipeline landscape is provided, which includes the disease overview and Non-Cystic Fibrosis Bronchiectasis treatment guidelines.

Non-Cystic Fibrosis Bronchiectasis Epidemiology https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Non-Cystic Fibrosis Bronchiectasis Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Non-Cystic Fibrosis Bronchiectasis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Peritoneal Dialysis Equipment Market: https://www.delveinsight.com/report-store/peritoneal-dialysis-equipment-market
• Drug-eluting Stents Market Market: https://www.delveinsight.com/report-store/drug-eluting-stents-market
• Sinusitis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market
• Pd-1 & Pdl1 Market: https://www.delveinsight.com/report-store/pd-1-and-pd-l1-inhibitors-competitive-landscape
• Cervical Dysplasia Market: https://www.delveinsight.com/report-store/cervical-dysplasia-market-insights
• Hypogonadism Market: https://www.delveinsight.com/report-store/hypogonadism-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.